Research desk · AMGN · Nasdaq

SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.

Amgen Inc. · Biological Products, (No Diagnostic Substances)

Amgen Inc. financial statements, chart, and peer compare from SEC filings.

Amgen Inc. (AMGN) develops biotechnology and life-science products.

Market cap
$239.07B
P/E
29.44
Op. margin
28.99%
Profit margin
22.27%
FCF margin
12.64%
ROE
69.78%

Related Health Care stocks: BMY stock financials · GILD stock financials · ABBV stock financials · REGN stock financials · THC stock financials

See Health Care moving on the anomaly desk

misprise.com
Watch / incomplete (<60) TTM Updated October 18, 2026 9:17 pm ← Screener
Primary research · 02

AMGN financial statements

Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.

Primary research · 03

AMGN stock peer compare

Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.

Focus chart

Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.

Supporting · 04

AMGN stock peer headlines

Yahoo Finance RSS for AMGN and the names in Compare.

Ticker Date Headline
Loading headlines…
Supporting · 05

AMGN stock price chart

Overlays follow the Compare table.

Chart loads when you scroll here
Supporting · 06

AMGN stock — research snapshot

Screen strengths and watchouts for AMGN stock from the latest Misprise snapshot.

Strengths

  • ROE 69.8% — efficient equity returns.
  • Operating margin 29.0% — solid operating leverage.
  • Profit margin 22.3% — durable bottom-line quality.
  • FCF margin 12.6% — cash conversion looks healthy.

Watchouts

  • Debt/equity 5.37 — elevated leverage risk.
  • PEG 10.01 — valuation looks rich vs growth.
  • Rev CAGR 5Y 7.7%
  • Rev CAGR 3Y 11.8%
  • EPS CAGR 5Y 2.9%
  • EPS CAGR 3Y 5.5%
  • FCF CAGR 5Y -3.9%
  • FCF CAGR 3Y -2.7%
Supporting · 07

AMGN stock FAQs

Short answers for AMGN stock — statements, sector, and how this page is meant to be used.

What is AMGN stock?

Amgen Inc. (AMGN) develops biotechnology and life-science products. AMGN stock sits in Health Care (Biological Products, (No Diagnostic Substances)), listed on Nasdaq.

Where can I find Amgen Inc. financial statements?

Amgen Inc. financial statements — income statement, balance sheet, and cash flow — are on this AMGN stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.

What happened to AMGN stock?

This page is a research snapshot of Amgen Inc. (AMGN) from the latest SEC filings in the Misprise database as of TTM. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.

Does this page show the AMGN stock price?

The live chart on this AMGN stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.

What sector is AMGN stock in?

Amgen Inc. is classified in Biological Products, (No Diagnostic Substances), inside the Health Care sector, and trades on Nasdaq. This page is a research snapshot, not a full company profile.

How do I read AMGN financial statements?

Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.

Where does the AMGN statement data come from?

Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.

Where can I find the AMGN income statement, balance sheet, and cash flow?

On this AMGN stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.

What is the Misprise Score for AMGN stock?

AMGN stock currently scores 50/100 (Watch / incomplete (<60)). Amgen Inc. scores weaker or incomplete on durable growth/quality inputs — leverage, coverage, and recent results deserve extra scrutiny. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.

How is the AMGN comparison winner decided?

Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.

What is the Anomaly Score on this AMGN page?

Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.

What does the green grant dot mean on AMGN stock?

A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.

Is AMGN stock a buy?

No recommendation either way. This AMGN stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell Amgen Inc..